Articles related to COMBINATION THERAPY
FDA Approves Irinotecan Liposome Combo in Metastatic Pancreatic Cancer
The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.
Hematology/Oncology February 20th 2024
Combination Treatment of HER2-Positive Early Breast Cancer with High Recurrence Risk
In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.
Oncology, Medical February 5th 2024
FDA Approves Pembrolizumab Combination for Advanced Cervical Cancer
In a major stride for cervical cancer treatment, the FDA-approved pembrolizumab in combination with CRT demonstrates significant improvement in progression-free survival for FIGO 2014 stage III-IVA patients, marking a pivotal change in therapeutic approaches.
Hematology/Oncology January 22nd 2024
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
The recent phase 3 trial has demonstrated that the combination of the KRAS G12C inhibitor, sotorasib, with the EGFR inhibitor, panitumumab, can lead to longer progression-free survival in patients with chemorefractory metastatic colorectal cancer.
Oncology, Medical January 2nd 2024
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.
Oncology, Medical November 13th 2023
Enfortumab Vedotin Plus Pembrolizumab Nearly Doubles PFS, OS in Bladder Cancer
The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.
Oncology, Medical November 6th 2023